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Purpose:  Age-related  macular  degeneration  (AMD)  is  the  most  common  cause  of  irreversible  central  vision  loss
worldwide.  Research  has  linked  AMD  susceptibility  with  dysregulation  of  the  complement  cascade.  Typically,
complement factor H (CFH), complement factor B (CFB), complement component 2 (C2), and complement component
3 (C3) are associated with AMD. In this paper, we investigated the association between complement factor D (CFD),
another factor of the complement system, and advanced AMD in a Caucasian population.
Methods: Six single nucleotide polymorphisms (SNPs), rs1683564, rs35186399, rs1683563, rs3826945, rs34337649,
and rs1651896, across the region covering CFD, were chosen for this study. One hundred and seventy-eight patients with
advanced AMD and 161 age-matched normal controls were genotyped. Potential positive signals were further tested in
another independent 445 advanced AMD patients and 190 controls. χ2 tests were performed to compare the allele
frequencies between case and control groups.
Results: None of the six SNPs of CFD was found to be significantly associated with advanced AMD in our study.
Conclusions: Our findings suggest that CFD may not play a major role in the genetic susceptibility to AMD because no
association was found between the six SNPs analyzed in the CFD region and advanced AMD.
Age-related macular degeneration (AMD) is the most
common cause of irreversible central vision loss worldwide
[1]. It can be divided into early and advanced (late) forms.
Early AMD is characterized by the presence of drusen or
pigmentary abnormalities in the retinal pigment epithelium
(RPE), while advanced AMD includes two clinical types—
geographic atrophy of the RPE (dry AMD) and choroidal
neovascularization  (wet  AMD).  Age-related  macular
degeneration is a complex disease caused by the combination
of genetic predisposition and environmental factors [2-4]. The
inheritance of AMD is polygenic and multifactorial: race, age,
smoking, body mass, and body mass index have all been
associated  with  AMD  [2,5-9].  In  the  past  five  years,
significant progress has been made in our understanding of
AMD genetics through studies that identified specific single
nucleotide  polymorphisms  (SNPs)  significantly  associated
with AMD. The discovery of the strongest associations of
AMD with the variants of complement factor H (CFH; OMIM
134370)  [10-13]  and  ARMS2/HTRA1  (age-related
maculopathy  susceptibility  2,  OMIM  611313;  the  high
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temperature requirement factor A1, OMIM: 602194) [14-17]
has led to new hypotheses regarding the pathogenesis of this
disease. CFH is primarily associated with the formation of
drusen that often characterizes both types of advanced AMD
in Caucasian populations, whereas ARMS2/HTRA1 is mainly
associated with wet AMD [18]. Other than these two major
loci,  three  other  members  of  the  complement  system,
complement component 2 (C2; OMIM 217000), complement
component 3 (C3; OMIM 120700), and complement factor B
(CFB; OMIM 138470), were also found to be associated with
AMD  [10,19-21].  Most  of  these  genes  are  complement
pathway-associated genes, with the products participating in
the alternative complement pathway and playing important
roles in the complement system. Many studies have provided
evidence  that  the  complement  system  is  involved  in  the
pathogenesis of AMD and may have a pivotal effect on the
formation  and  development  of  the  disease  [13,22-24].
However, the specific role of the complement system in the
etiology  of  AMD  is  difficult  to  elucidate,  and  questions
remain as to whether other components from this system are
associated with AMD.
Complement factor D (CFD) is a protein of the trypsin
family encoded by the CFD gene (OMIM 134350) and is
involved  in  the  alternative  complement  pathway  of  the
complement system [25,26]. CFD is unique among serine
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2273proteases in that it requires neither enzymatic cleavage for
expression of proteolytic activity nor inactivation by a serpin
for its control [27]. It is best known for its role in humoral
suppression  of  infectious  agents  and  has  a  high  level  of
expression  in  fat,  suggesting  a  role  for  adipose  tissue  in
immune system biology (CFD). In this study, we investigated
the association of CFD with advanced AMD in a Caucasian
population.
METHODS
Subjects and clinical diagnosis: This study was approved by
the Institutional Review Board of the University of California,
San Diego. Informed consent was signed by all subjects before
participation in the study. One hundred and seventy-eight
nonfamilial advanced AMD patients and 161 age-matched
normal controls (60 years or older with no drusen or RPE
changes) as well as an independent replication cohort with 445
nonfamilial advanced AMD patients and 190 age-matched
normal controls were recruited using the standard ophthalmic
examination  protocol.  Grading  was  performed  using  a
standard  grid  classification  suggested  by  the  International
Age-related  Maculopathy  (ARM)  Epidemiological  Study
Group  for  the  age-related  maculopathy  and  age-related
macular degeneration group [28]. All the participants were
Caucasian.
Genotyping: Six SNPs, rs1683564, rs35186399, rs1683563,
rs3826945, rs34337649, and rs1651896 at the CFD locus
were chosen, which were either tag SNPs or those that might
affect the function of CFD (Figure 1). A Caucasian cohort of
178  advanced  AMD  patients  was  genotyped  and  allele
frequencies  were  compared  with  161  age-  and  ethnicity-
matched normal controls by laboratory personnel blinded to
the case/control status. Potential positive findings were tested
for replication in an independent cohort of 445 advanced
AMD patients and 190 normal controls.
Genotypes  of  six  SNPs  were  achieved  by  primer
extension  of  multiplex  PCR  products  followed  with  a
SNaPshot  using  an  ABI  3100  genetic  analyzer  (Applied
Biosystems, Foster City, CA).
Statistical  analysis:  Deviation  from  Hardy–Weinberg
equilibrium was assessed, with a statistical significance level
of 0.01. A chi-square test was performed to assess evidence
for association. The statistical significance level was adjusted
by  Bonferroni  correction.  Linkage  disequilibrium  (LD)
patterns and haplotype blocks were defined using Haploview
4.1.
RESULTS
We  genotyped  six  SNPs  that  tag  the  majority  of  CFD
haplotypes and investigated allelic association with AMD.
Four  SNPs,  rs1683564,  rs35186399,  rs1683563,  and
rs3826945, located either at the promoter region, exon, or
intron of CFD, exhibited no association with advanced AMD
in our study population. The SNP rs34337649, in exon 5 of
CFD, showed no polymorphisms in our data (Table 1).
Of the six SNPs, rs1651896, which is located at the 3′
region of CFD, was found to be marginally associated with
advanced AMD (P(allelic)=0.07, risk allele A: 37.4% in cases
versus  30.7%  in  controls)  in  a  Caucasian  cohort  of  178
advanced AMD cases and 161 normal controls. The result was
further investigated in an independent replication cohort of
445 advanced AMD patients and 190 controls. No further
significant association was observed for either the replication
Figure 1. Six single nucleotide polymorphisms (SNPs) on complement factor D (CFD). Shown is the corresponding location of each SNP on
CFD (chromosome:19; location:19p13.3) that was chosen in this study.
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37.6% in controls) or the combined cohort (P(allelic)=0.223,
risk allele A: 37.2% in cases versus 34.5% in controls, Table
2).
Linkage disequilibrium patterns and haplotype blocks
were  defined  by  combining  the  six  SNPs  (Figure  2).  No
significant association was found between the haplotypes and
AMD phenotypes. The SNP rs34337649 was not shown in the
plot because it was not a detected polymorphism in our data
set.
DISCUSSION
The alternative complement pathway is one of three distinct
complement pathways and is important in the clearance and
recognition of pathogens in the absence of antibodies [29]
(Figure 3). It is triggered by spontaneous C3 hydrolysis to
form C3a and C3b, which makes C3b capable of binding to a
pathogenic membrane surface. After binding with an activator
membrane, C3b is bound by CFB to form C3bB. Complement
factor H acts as one of the primary regulators by inhibiting the
binding of CFB to C3b and also by degrading C3b. In the
presence of CFD, C3bB is cleaved into C3bBa and C3bBb
(C3 convertase). After hydrolysis of C3, C3 convertase and
C3b become C3bBbC3b, which cleaves C5 into C5a and C5b.
A  membrane  attack  complex  (MAC)  is  formed  through
Figure 2. Linkage disequilibrium (LD) plot of six single nucleotide
polymorphisms  (SNPs)  on  complement  factor  D  (CFD).  The
physical position of each SNP is shown above the plot. Darker shades
of red indicate higher values of the LD coefficient (D'). The numbers
in pink and white squares show the % of D' between SNPs with
incomplete LD. Blue squares with no number indicate a pairwise
linkage disequilibrium of 1 between SNPs, supported by logarithm
(base 10) of odds (lod) scores < 2.
TABLE 1. ASSOCIATION BETWEEN 5 SINGLE NUCLEOTIDE POLYMORPHISMS (SNPS) ON COMPLEMENT FACTOR D (CFD) AND ADVANCED AGE RELATED MACULAR
DEGENERATION (AMD)
SNP Minor
allele
Frequency in
case
HWE in case Frequency in
control
HWE in
control
Frequency in
HapMap
p (allelic)
rs1683564 G 0.424 8.96E-01 0.409 1.57E-01 0.460 (CEPH) 0.710
rs35186399 A 0.006 9.97E-01 0.003 9.99E-01 N.A. 0.658
rs1683563 G 0.371 3.47E-01 0.414 8.21E-01 0.353 0.253
rs3826945 G 0.346 9.18E-01 0.309 9.68E-01 0.351 0.318
rs34337649 T 0 N.A. 0 N.A. N.A. N.A.
        Shown are minor alleles for each SNP on CFD; frequencies for our advanced AMD, control groups and HapMap European
        groups; Hardy–Weinberg equilibrium (HWE) test; and P(allelic) values. (The P(allelic) value cannot be calculated when there
        is a count equal to zero).
TABLE 2. ASSOCIATION BETWEEN COMPLEMENT FACTOR D (CFD) SINGLE NUCLEOTIDE POLYMORPHISM (SNP) RS1651896 AND ADVANCED AGE
RELATED MACULAR DEGENERATION (AMD) IN THE DISCOVERY, REPLICATION AND COMBINATION COHORTS
Cohort Phenotype N MAF (A) HWE p (allelic)
Discovery Advanced AMD 178 0.374 4.21E-01 0.07
Cohort Control 161 0.307 9.97E-01  
Replication Advanced AMD 445 0.372 9.52E-01 0.882
Cohort Control 190 0.376 8.41E-01  
Combination Advanced AMD 623 0.372 9.05E-01 0.223
Cohort Control 351 0.345 9.21E-01  
HapMap-CEU Control 112 0.321    
       Shown are the corresponding numbers of the CFD SNP rs1651896 for both advanced AMD and control groups in the discovery
        cohort, replication cohort, and combination cohort. Frequencies for the minor allele in our cohorts and HapMap European group,
        hardy Weinberg equation (HWE) test, and P(allelic) values are given.
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2275Figure  3.  The  alternative  complement  pathway.  The  principal
components of the alternative complement pathway from C3 to the
stage of membrane attack complex (MAC) formation are shown in
detail. Complement factor H (CFH) with the dotted arrow acts as an
inhibiting  regulator  while  Complement  factor  B  (CFB)  and
Complement factor D (CFD) with the filled arrows are activators.
subsequent reactions, which inserts into the cell membrane
and initiates cell lysis [18,30,31]. In this pathway, CFB and
CFD are involved in the activation and amplification loop,
whereas  CFH  is  a  fluid  phase  inhibitor.  To  keep  the
complement activity under control, the competition between
CFH and CFB binding to C3b on the host or pathogen cells
needs to be tightly regulated. How this control is achieved is
not completely clear [18].
Compared with other complement factors, CFH, C3, and
CFB have been associated with AMD in many independent
studies. However, the exact role they play in the pathogenesis
of AMD and whether their effects are mediated through the
complement system or through another pathway is poorly
understood. Previously, CFD was studied using a CFD  −/−
mouse  model,  with  the  conclusion  that  eliminating  the
alternative  pathway  was  neuroprotective  and  reduced
photoreceptor  susceptibility  to  light-induced  damage  [25].
Contrary to this finding, no significant association between
CFD SNPs and advanced AMD was found in this study. Due
to the dearth of information about the relationship between
CFD and AMD, further research in other populations may be
warranted. Our results suggest it is unlikely that CFD is a
major functional candidate gene conferring risk for AMD.
However, due to the relatively small sample size, this study
has limited power to detect minor effects. Extended cohorts
will be needed to confirm the genetic role of CFD. Future
research should also focus on a comprehensive understanding
of genetic variants throughout all pathways of the complement
system. By identifying high risk variants and improving our
understanding of the complement system, early intervention
for patients at risk of developing AMD and novel gene-based
treatments may become a reality.
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